YTB323 for treatment-resistant generalized myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell therapy (YTB323) for people with generalized myasthenia gravis that hasn't been well-controlled by standard treatments. The goal is to see if it can safely improve symptoms and change how the immune system attacks the nerves.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of generalized myasthenia gravis with positive antibodies (AChR or MuSK).
- Your MG is moderate to severe (MGFA Class III or IVa) but not in a crisis or very severe.
- Your symptoms are significant (MG-ADL score of 6 or more) despite trying at least 2 different non-steroid immunosuppressants.
- You are on a stable dose of steroids and willing to reduce to no more than 10 mg prednisone per day before the procedure.
- You have not had prior CAR-T cell therapy, gene therapy, or anti-CD19 treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial tests a new medication called Telitacicept for people with generalized myasthenia gravis (gMG). The goal is to see if it can reduce muscle weakness and improve daily function. You may be able to join if you have moderate to severe symptoms and have not had recent thymoma or other serious health issues.
This trial tests whether an injection of special immune cells called STAR-T cells can help people with generalized myasthenia gravis. It is for those whose symptoms are moderate to severe and haven't improved enough after at least two standard treatments.
This study tests a new drug called SHR-2173 to help people with generalized myasthenia gravis (a condition where muscles weaken because the immune system blocks communication between nerves and muscles). The drug is designed to work with treatments you're already taking to improve muscle strength and reduce symptoms.
This trial tests a new cell therapy called anitocabtagene autoleucel (anito-cel) for people with generalized myasthenia gravis (gMG) that is not well controlled with current treatments. The goal is to see if it can reduce symptoms and improve quality of life.
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.